News

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs like stomatitis before the first outpatient clinic visit.

Phase 2 findings show clinical responses and improved survival with evorpacept in patients with HER2-positive gastric/gastroesophageal cancer.

While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.

The phase 2 FDZL-001 trial showed high overall survival and progression-free survival rates with camrelizumab plus Nab-POF in patients with gastric/GEJ cancer.

The EA2186 trial was the first study specifically designed to test chemotherapy in older adults with advanced pancreatic cancer who were considered vulnerable.

Analysis of the NAPOLI 3 trial showed that lower doses of liposomal irinotecan or oxaliplatin did not reduce survival in patients with pancreatic ductal adenocarcinoma.

Susumu Hijioka, MD, discussed how a lower dose of everolimus may help address certain adverse events like oral mucositis and hypoglycemia.

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, but not longer, follow-ups.

First-line nivolumab plus ipilimumab was shown to be effective and well-tolerated in patients with unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Aspirin reduced disease recurrence in patients with PI3K-mutated colorectal cancer, underscoring the value of early genomic testing.

Cabozantinib prolonged PFS compared to placebo for patients with extrapancreatic NETs starting in the GI tract in a subgroup analysis of the CABINET trial.

Preoperative sintilimab with chemoradiotherapy boosted pathological complete response rates in patients with resectable, locally advanced esophageal squamous cell carcinoma.

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing results for treatment decision-making.

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus chemotherapy between early and late responders with ESCC.

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Oncology nurses can provide patients with information regarding the risks and benefits of these medications in cancer treatment.

Everolimus plus lanreotide resulted in a progression-free survival of 29.7 months in patients with gastroenteropancreatic neuroendocrine tumors, compared with 11.5 months with everolimus monotherapy.

Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.

Pembrolizumab, added to preoperative radiation and surgery, prolonged disease-free survival in patients with soft tissue sarcoma of the extremity.

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.

Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a CLEER-001 trial.

Device programming encounters near the end of life occurred in nearly half of patients with ICDs, offering a potential opportunity for goals-of-care discussions.

The FELIX trial demonstrated that obe-cel induced durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer.

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to confirm this finding.

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.